Kite Enters into License Agreement with Arcellx for CART-ddBCMA in Multiple Myeloma
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 12 (Table of Contents)
Published: 16 Dec-2022
DOI: 10.3833/pdr.v2022.i12.2753 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In a bid to expand its cell therapy portfolio, Kite Pharma has entered into a licensing agreement with Arcellx in a deal worth up to US$4...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS